Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.

International journal of biological sciences·2026
Same author

Proinflammatory macrophage secretome enhances temozolomide sensitivity in glioblastoma via pSTAT3-mediated downregulation of DNA repair enzymes.

Scientific reports·2025
Same author

Treatment of presumed aseptic non-union of the humeral shaft by osteosynthesis combining intramedullary nailing and screw plate.

Acta orthopaedica Belgica·2024
Same author

Retraction Note: P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.

Oncogene·2024
Same author

MAPK11 (p38β) is a major determinant of cellular radiosensitivity by controlling ionizing radiation-associated senescence: An in vitro study.

Clinical and translational radiation oncology·2023
Same author

Treatment of COVID-19 pneumonia with low-dose radiotherapy plus standard of care versus standard of care alone in frail patients : The SEOR-GICOR IPACOVID comparative cohort trial.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2023

Related Experiment Video

Updated: Nov 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models.

R Pascual-Serra1, D M Fernández-Aroca1, S Sabater2

  • 1Laboratorio de Oncología, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Unidad Asociada de Biomedicina UCLM, Unidad Asociada al CSIC, Albacete, Spain.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|December 14, 2020
PubMed
Summary

The p38β protein is key to gemcitabine’s ability to enhance radiation therapy effectiveness. Targeting p38β could improve cancer treatment when gemcitabine is combined with radiation.

Keywords:
GemcitabineMAPK11 (p38β)MAPK14 (p38α)RadiosensitivitySarcomap38MAPK

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Experiment Videos

Last Updated: Nov 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gemcitabine is an anticancer drug with radiosensitizing properties.
  • The p38 mitogen-activated protein kinase (MAPK) pathway influences cellular response to gemcitabine.
  • The precise mechanism of gemcitabine's radiosensitizing effect is not fully understood.

Purpose of the Study:

  • To investigate the role of the p38MAPK signaling pathway in gemcitabine-induced radiosensitivity.
  • To identify specific p38MAPK isoforms involved in this process.

Main Methods:

  • Utilized human and mouse sarcoma cell lines.
  • Modulated p38MAPK activity using pharmacological inhibitors and genetic knockdown (shRNAs).
  • Assessed cell viability, gene expression, apoptosis, and radiation response using MTT assays, western blot, RT-qPCR, and clonogenic assays.

Main Results:

  • Inhibiting the p38MAPK pathway abolished gemcitabine's radiosensitizing effect.
  • Knockdown of MAPK14 (p38α) increased gemcitabine resistance but did not alter radiosensitivity.
  • Specific knockdown of MAPK11 (p38β) completely eliminated gemcitabine's radiosensitizing potential and increased drug resistance.

Conclusions:

  • p38β is identified as a critical mediator of gemcitabine's radiosensitizing effects.
  • p38α is not implicated in gemcitabine's radiosensitivity.
  • p38β status should be considered when combining gemcitabine with ionizing radiation in cancer therapy.